Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

4-Star Stocks Poised to Pop: Novo Nordisk
Motley Fool
Wednesday, December 29, 2010 - 11:34am
tags:
Novo Nordisk
Impax gets FDA approval for generic antibiotic
Yahoo/AP
Wednesday, December 29, 2010 - 11:33am
tags:
generics, Impax, FDA, DORYX
Abbott the Only One Left in the Osteoarthritis Game
Seeking Alpha
Wednesday, December 29, 2010 - 11:28am
tags:
Abbott Laboratories, osteoarthritis, JNJ, AstraZeneca, Pfizer, Regeneron, Sanofi
DARA Biosciences Looks to Raise $4M
TheStreet.com
Wednesday, December 29, 2010 - 10:55am
tags:
DARA Biosciences
Aastrom Biosciences' Uptrend Fueled by More Than Just Market Momentum
Seeking Alpha
Wednesday, December 29, 2010 - 10:53am
tags:
Aastrom, Cell Therapeutics, StemCells
Savient Pharma starts search for new CEO
Yahoo/AP
Wednesday, December 29, 2010 - 10:51am
tags:
Pharma CEOs, Savient
GSK pitches Votrient rebate if trial favors Sutent
Fierce Pharma
Wednesday, December 29, 2010 - 10:50am
tags:
GSK, Sutent, Votrient, cancer
AstraZeneca's Brennan Poaches Pfizer to Rebuild Research
Bloomberg
Wednesday, December 29, 2010 - 10:47am
tags:
Pfizer, R&D, AstraZeneca, David Brennan, Pharma CEOs
Skystar Bio-Pharmaceutical Co (SKBI): Zacks Rank Buy
Yahoo/Zacks.com
Wednesday, December 29, 2010 - 10:44am
tags:
Skystar Bio-Pharmaceutical, China
Burned By Pfizer
CNBC
Wednesday, December 29, 2010 - 10:43am
tags:
Pfizer
Merck’s Cholesterol Drug May Become Catalyst for Future Growth
Seeking Alpha
Wednesday, December 29, 2010 - 10:42am
tags:
Merck, Anacetrapib, cholesterol
The Top Dividend Aristocrats in Pharma and Biotech
Motley Fool
Wednesday, December 29, 2010 - 10:41am
tags:
dividends, JNJ, Abbott Laboratories, Eli Lilly
Party not over for Repros shares
Bizjournals.com
Tuesday, December 28, 2010 - 4:01pm
tags:
Repros Therapeutics, Androxal, Proellex
FDA Delay Could Be Very Bad Omen For MannKind
Forbes
Tuesday, December 28, 2010 - 3:59pm
tags:
FDA, MannKind, inhaled insulin, Afrezza
Analyzing Volatility and Making a Trade in Pfizer
Yahoo/TheStreet.com
Tuesday, December 28, 2010 - 3:58pm
tags:
Pfizer, King
Takeovers Vs. R&D: What Will Drive Biotech Stocks in 2011?
Seeking Alpha
Tuesday, December 28, 2010 - 2:08pm
tags:
R&D, biotech, M&A, Cepheid, Abbott Laboratories, Bristol-Myers Squibb, Dendreon, Elan, Biogen Idec, JNJ, King, Neurocrine, Pfizer, SPDR Biotech
Biogen Idec begins selling Tysabri in India
Bizjournals.com
Tuesday, December 28, 2010 - 1:11pm
tags:
Indian, Tysabri, Biogen Idec, MS, multiple sclerosis
Cephalon’s Jet Lag Hopes For Nuvigil Are Grounded
Pharmalot
Tuesday, December 28, 2010 - 1:10pm
tags:
NUVIGIL, jet lag, Cephalon
MannKind Says FDA Will Take Another Four Weeks on Insulin Decision
WSJ Online
Tuesday, December 28, 2010 - 1:08pm
tags:
FDA, inhaled insulin, MannKind, Afrezza
BioSante Attracts Institutional Investors Ahead of Key FDA Catalysts in 2011
Seeking Alpha
Tuesday, December 28, 2010 - 11:58am
tags:
BioSante, YM BioSciences, Lannett, EnteroMedics

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.